Impact of anticoagulation regimen prior to revascularization in patients with non-ST-segment elevation acute coronary syndromes: The ACUITY trial

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
Tobias GeislerGregg W Stone

Abstract

To evaluate the impact of antithrombotic regimens during the medical phase of treatment among 13,819 patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) treated with an early invasive strategy in the acute catheterization and urgent intervention triage strategy (ACUITY) trial. Endpoints included composite major adverse cardiac events (MACE), major bleeding, and net adverse clinical events (NACE; MACE or major bleeding). The median (interquartile range) duration of antithrombin use in the medical only treatment phase was 6.5 (1.8-22.5) hours. MACE, major bleeding, and NACE during the medical only phase occurred in 63 (0.5%), 117 (0.9%), and 178 (1.3%) patients, respectively. MACE rates in the medical-treatment-only phase were not significantly different between the four randomized medical regimens used (heparin alone, bivalirudin alone, heparin plus a glycoprotein IIb/IIIa inhibitor [GPI], and bivalirudin plus GPI) (Ptrend  = 0.65). The lowest rates of major bleeding and NACE during the medical treatment phase occurred in patients treated with bivalirudin alone (Ptrend  = 0.0006 and Ptrend  = 0.0004, respectively). In patients with NSTE-ACS undergoing an early invasive strategy, treatment with bivalirudin ...Continue Reading

References

Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Oct 3, 2006·Journal of the American College of Cardiology·Anthony A BavryArman T Askari
Nov 25, 2006·The New England Journal of Medicine·Gregg W StoneUNKNOWN ACUITY Investigators
Feb 15, 2007·JAMA : the Journal of the American Medical Association·Gregg W StoneUNKNOWN ACUITY Investigators
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Dec 7, 2007·JAMA : the Journal of the American Medical Association·Gregg W StoneUNKNOWN ACUITY Investigators
May 24, 2008·The New England Journal of Medicine·Gregg W StoneUNKNOWN HORIZONS-AMI Trial Investigators
Aug 21, 2008·European Heart Journal·Andrzej BudajUNKNOWN OASIS 5 Investigators
Apr 1, 2009·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN EARLY ACS Investigators
May 30, 2009·Journal of the American College of Cardiology·Brendan J DoyleDavid R Holmes
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Nov 17, 2009·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PLATFORM Investigators
Nov 15, 2011·The New England Journal of Medicine·Adnan KastratiUNKNOWN ISAR-REACT 4 Trial Investigators
Mar 12, 2013·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PHOENIX Investigators
Sep 3, 2013·The New England Journal of Medicine·Gilles MontalescotUNKNOWN ACCOAST Investigators
Nov 1, 2013·The New England Journal of Medicine·Philippe Gabriel StegUNKNOWN EUROMAX Investigators

❮ Previous
Next ❯

Citations

Aug 18, 2016·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Jorge A Belardi, Mariano Albertal

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

© 2021 Meta ULC. All rights reserved